Fig. 4: Anti-CD25-mediated Treg depletion mitigates tumor growth. | Leukemia

Fig. 4: Anti-CD25-mediated Treg depletion mitigates tumor growth.

From: Transient regulatory T-cell targeting triggers immune control of multiple myeloma and prevents disease progression

Fig. 4

A Mice with engrafted MM were treated twice with anti-CD25-antibody (100 µg/mouse/injection i.p.). B Tumor progression was monitored with non-invasive BLI. C Tumor growth relative to the signal at the start of the therapy. Two-way ANOVA with Sidak’s multiple comparisons test: day14 ∗P ≤ 0.05 (n = 4–5).

Back to article page